Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone
- 1 March 1986
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 16 (2) , 91-94
- https://doi.org/10.1007/bf00256155
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanomaCancer, 1985
- Clinical safety and tolerance of mitoxantrone (Novantrone)Cancer Treatment Reviews, 1983
- Mitoxantrone (novantrone): a review of experimental and early clinical studiesCancer Treatment Reviews, 1983
- Experimental model of doxorubicin extravasation in the mouseJournal of Pharmacological Methods, 1980
- Mechanism of DNA-binding of some aminoalkylamino-derivatives of anthraquinone and naphthacenequinoneJournal of Pharmacy and Pharmacology, 1980
- Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugsCancer Treatment Reviews, 1980
- Phase I clinical trial of mitoxantrone: A new anthracenedione anticancer drugCancer Chemotherapy and Pharmacology, 1980
- Kinetics of intravenous melphalanClinical Pharmacology & Therapeutics, 1979
- Inapparent infiltrations associated with vindesine administrationMedical and Pediatric Oncology, 1979
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977